Day One (DAWN) Q1 2025: Ojemda Scripts Jump 16% as Depth Strategy Accelerates
Ojemda, Day One’s core therapy for pediatric low-grade glioma (PLGG), fueled double-digit script growth in Q1, as management sharpened focus on deepening account penetration and expanding prescriber confidence. The company’s disciplined cost structure and sizable cash reserves position it to weather biotech headwinds while pipeline programs and business development remain active levers for future expansion.
Summary
- Script Growth Outpaces Prescriber Expansion: Deeper adoption in priority accounts is now the primary commercial lever.
- Pipeline and Portfolio Diversification: Firefly 2 and Day 301 development progress reinforce multi-program strategy.
- Financial Flexibility Remains High: Cash position supports disciplined investment and business development without near-term financing needs.
Performance Analysis
Day One’s Q1 performance was defined by Ojemda’s accelerating commercial momentum, with total quarterly scripts surpassing 900, up 16% from the prior quarter. This demand translated into $30.5 million in net product revenue, as prescriber confidence and patient duration on therapy continued to increase. The company’s script growth outpaced revenue growth, reflecting both the impact of seasonality and a January price increase that nudged gross-to-net adjustments toward the upper end of guidance.
Operational discipline was evident in a 4% sequential decline in operating expenses (excluding one-time charges), even as investment in clinical development and commercial support remained steady. With a cash balance of $473 million and zero debt, Day One’s financial health stands out in a sector facing existential macro headwinds. The company expects operating expenses to remain consistent for the year, balancing targeted growth initiatives with prudent cost management.
- Ojemda Drives Core Growth: Prescription and revenue gains were led by increased depth within top-priority accounts.
- Seasonality Managed Effectively: Early Q1 slowdowns from holidays and deductible resets were offset by strong April patient starts.
- Pipeline Execution on Track: Firefly 2 enrollment and Day 301 dose escalation are progressing per plan, supporting future portfolio expansion.
Management’s focus has shifted from broadening prescriber base to deepening usage within existing accounts, especially as more conservative pediatric oncologists build experience and confidence with Ojemda. This is expected to drive durable, long-term value creation as the therapy becomes further entrenched in the treatment landscape.
Executive Commentary
"Our consistent growth each quarter since launch and the market dynamics we've observed over the past 12 months have further reinforced that Ojemda is a foundational opportunity for day one that will drive durable, long-term value creation."
Dr. Jeremy Bender, Chief Executive Officer
"By maintaining a disciplined financial strategy as a cornerstone to building long-term durable growth, we anticipate that costs and operating expenses will remain relatively consistent the rest of the year with some quarter to quarter variability, which allows us to invest strategically in opportunities that support growth while prioritizing our clinical development plan."
Charles York, Chief Operating and Financial Officer
Strategic Positioning
1. Ojemda: Depth-Driven Commercial Expansion
Day One’s commercial strategy now prioritizes increasing the depth of Ojemda prescribing within existing accounts, particularly among Priority 1 and 2 centers. The company has achieved 100% trial among Priority 1 and 75% among Priority 2 accounts, with efforts shifting to encourage broader patient eligibility and earlier-line use. This approach recognizes the conservative nature of pediatric oncology, where long-term safety and physician confidence are paramount. Management expects that continued education and real-world experience will be key to accelerating adoption.
2. Pipeline Progress and Portfolio Expansion
Firefly 2, the confirmatory trial for Ojemda’s frontline use, remains on track for full enrollment in the first half of 2026, supporting potential label expansion. The Day 301 antibody-drug conjugate (ADC) program is advancing through phase 1A dose escalation, targeting adult solid tumors with high PTK7 expression. Management is judicious about disclosing specifics, citing competitive reasons, but emphasized that both safety and early efficacy signals will drive future go/no-go decisions. These programs underpin Day One’s ambition to build a multi-program clinical portfolio beyond pediatric oncology.
3. Financial Resilience and Business Development Optionality
Day One’s $473 million cash balance and lack of debt provide significant strategic flexibility, insulating the company from near-term capital markets volatility. Management reiterated that no additional financing is anticipated under current plans. This strong balance sheet supports continued investment in pipeline programs and positions Day One to pursue business development opportunities with a high bar for quality and strategic fit. The company remains actively engaged in evaluating new assets to supplement organic growth.
4. Navigating a Conservative Prescriber Base
Pediatric oncologists’ risk aversion and focus on long-term safety require a tailored commercial approach, with emphasis on building trust through data, peer experiences, and patient support. The company’s educational initiatives and upcoming two-year Firefly One follow-up data are expected to further support Ojemda’s positioning as second-line standard of care, especially in the BRAF fusion PLGG segment where approved alternatives are limited.
Key Considerations
This quarter’s results highlight Day One’s evolving commercial and operational priorities, as the company leverages its core Ojemda franchise to build a broader, multi-program platform in oncology.
Key Considerations:
- Depth Over Breadth in Commercial Execution: Future growth increasingly depends on deeper patient penetration within established accounts, not just new prescriber activation.
- Physician Confidence as a Growth Catalyst: Conservative pediatric specialists require ongoing education and real-world evidence to expand Ojemda usage earlier in treatment.
- Pipeline Progression is a Key Long-Term Lever: Firefly 2 and Day 301 milestones could unlock new revenue streams and diversify risk beyond Ojemda.
- Financial Strength Enables Selective Expansion: Ample liquidity allows Day One to pursue business development without diluting focus or financial discipline.
Risks
Key risks include the slow adoption curve inherent to rare disease launches, especially given the conservative pediatric oncology community and the need for long-term safety data. Pipeline execution risk remains, particularly for Day 301, where early-stage development may not translate to clinical or commercial success. Macroeconomic volatility and potential pricing pressures in both the US and Europe could also impact future performance, despite the current strong cash position.
Forward Outlook
For Q2 2025, Day One guided to:
- Continued steady growth in Ojemda scripts and revenue, driven by increasing depth in top-priority accounts
- Operating expenses expected to remain consistent with Q1 levels, with some quarter-to-quarter variability
For full-year 2025, management maintained guidance:
- No additional financing required under current operating plans
Management highlighted several factors that will shape the year:
- Firefly 2 enrollment progress and upcoming two-year Firefly One data as catalysts for prescriber confidence
- Ongoing business development activity, with a high bar for new asset integration
Takeaways
Day One’s Q1 results reinforce the company’s disciplined commercial execution and pipeline-driven growth thesis.
- Ojemda’s Entrenchment Deepens: Script growth and high on-therapy duration signal increasing physician trust, with a clear path to further market penetration as depth initiatives take hold.
- Pipeline and Portfolio Optionality: Progress on Firefly 2 and Day 301, coupled with business development flexibility, provide multiple shots on goal for long-term value creation.
- Watch for Prescriber Behavior Shifts: Investors should monitor the pace of depth gains in Priority 1 and 2 accounts, as well as signals from upcoming clinical data that could accelerate Ojemda’s adoption curve.
Conclusion
Day One enters the remainder of 2025 with strong commercial momentum, operational discipline, and ample financial resources. The company’s focus on deepening Ojemda adoption, advancing its pipeline, and selectively expanding the portfolio positions it for durable growth, though execution in a cautious prescriber landscape remains the key variable to watch.
Industry Read-Through
Day One’s experience underscores the importance of depth-driven strategies in rare disease and pediatric oncology markets, where prescriber conservatism and long-term safety concerns slow adoption curves compared to adult oncology launches. Biotechs with strong balance sheets and disciplined cost controls are best positioned to navigate macro volatility and fund pipeline bets. The company’s steady progress in both commercial and clinical arenas signals that multi-program platforms with targeted business development can mitigate single-asset risk and support valuation resilience across the sector.